EU and EUREKA Launched Eurostars Programme for Research-Performing SMEs

EurostarsEurope has taken "another step in the realisation of the European Research Area, this time to the benefit of SMEs", according to EU Science and Research Commissioner Janez Potocnik, who helped to launch EUREKA's Eurostars programme. The programme will provide financial support, from both EU and the EUREKA member country funds, to Europe's young and innovative companies, described by Mr Potocnik as the 'lifeblood' of Europe's economy. The programme is aimed specifically at a niche market of research and innovation-performing businesses that fulfil the EU-adopted definition of an SME, are based in a country participating in Eurostars, and that invest 10% or more of their annual turnover in research.

"SMEs are the driving motor of the European economy because they are flexible. They can adapt quickly to the needs of the market," said the Commissioner.

Importantly, the initiative has been welcomed by the SME community. Speaking at the launch, chairman of the European Federation of high-tech SMEs, Emmanuel Leprince, spoke of his 'high expectations' for the programme. He also talked of a 'glass ceiling' that is preventing most SMEs from reaching their full potential. Eurostars will help these young companies, so often considered by investors as the 'dangerous option', to get a foot on the ladder.

The attraction of Eurostars is that it is designed specifically for SMEs involved in research, said Mr Leprince. "The Commission tackles red tape, regulations, standards etc. These are all important issues, but they are not the specific problems of SMEs," he explained.

Some SME representatives would however like to see the criteria for participation widened so that more companies can benefit. Ullrich Schröder, research and development (R&D) advisor at the European craft and SME employers' organisation (UEAPME), said that the number of SMEs investing 10% or over in research is quite small, and that the barrier should be lowered to 5% in line with the definition of a high-tech SME used by the Organisation for Economic Cooperation and Development (OECD).

Representing the Slovenian Presidency of EUREKA, Ales Mihelic, General Director of the Slovenian Ministry of Higher Education, Science and Technology, conceded that 10% is quite high, but pointed out that EUREKA has made it easier for more companies to participate by saying that they can also invest 10% of their full-time equivalent (FTE) in R&D.

Mr Potocnik highlighted how Eurostars will complement existing EU initiatives intended to support SMEs conducting research. Under the Sixth Framework Programme (FP6) the Commission set the target of having SMEs make up 15% of project participants. This target proved difficult to meet in some areas however. Under FP7, the Commission has simplified administrative procedures, increased the funding of SME projects from 50% to 75% of the project's cost, and introduced the guarantee fund. All of these measures are intended to make it easier for SMEs to participate in FP7.

But as the Commissioner pointed out, "In FP7 Cooperation projects, SMEs aren't usually leading the projects." Eurostars will enable SMEs to do just that, benefitting from €100 million in Commission funding and €300 million from 22 EU Member States and five countries associated to FP7. This capital is expected to attract a further €400 million in private investment.

"Eurostars fills a gap that was existing, using tools that were on our market but not used in this combination," said Mr Potocnik. The Commission's participation comes under Article 169 of the EU Treaty, which allows for the participation of the Community in research programmes run jointly by a number of EU Member States.

The Commissioner referred to these new and closer links between EUREKA and the framework programmes as a marriage. Alluding to questions over the Commission's commitment to funding Eurostars beyond its initial six-year timeframe, he said: "As we all know, in a marriage, it is not enough to say 'yes' only at the beginning. You have to show that you mean it constantly."

The imagery continued as the Commissioner concluded his speech, claiming that he was happy to be the best man at this marriage, and wishing Eurostars a long and happy life, with lots of healthy SMEs.

For further information, please visit:
http://www.eurostars-eureka.eu

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Accelerating NHS Digital Maturity: Paper…

Digitised clinical noting at South Tees Hospitals NHS Foundation Trust is creating efficiencies for busy doctors and nurses. The trust’s CCIO Dr Andrew Adair, deputy CCIO Dr John Greenaway, and...

Customized Smartphone App Shows Promise …

A growing body of research indicates that older adults in assisted living facilities can delay or even prevent cognitive decline through interventions that combine multiple activities, such as improving diet...

AI Tool Helps Predict Who will Benefit f…

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who...

New Study Shows Promise for Gamified mHe…

A new study published in Multiple Sclerosis and Related Disorders highlights the potential of More Stamina, a gamified mobile health (mHealth) app designed to help people with Multiple Sclerosis (MS)...

AI in Healthcare: How do We Get from Hyp…

The Highland Marketing advisory board met to consider the government's enthusiasm for AI. To date, healthcare has mostly experimented with decision support tools, and their impact on the NHS and...

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

New AI Tool Accelerates Disease Treatmen…

University of Virginia School of Medicine scientists have created a computational tool to accelerate the development of new disease treatments. The tool goes beyond current artificial intelligence (AI) approaches by...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...